Abstract Number: 0534 • ACR Convergence 2020
National Variation and Factors Associated with Long-term Opioid Use for Non-cancer Pain in the First Year of Use
Background/Purpose: Physician prescribing behaviour has been described as a key driver of rising opioid prescriptions and long-term opioid use. However, the effect of prescribers requires…Abstract Number: 0550 • ACR Convergence 2020
Mapping Multimorbidity Using Drug Concept Unique Identifiers (RxCUIs) via the Rx-Risk Comorbidity Index
Background/Purpose: Identifying and accurately classifying comorbid conditions in large, real-world data sources is crucial for cohort establishment and confounder adjustment. However, the ability to conduct…Abstract Number: 0594 • ACR Convergence 2020
Mechanical and Temperature Stress During Biologic Shipments to Rheumatology Patients
Background/Purpose: Biologic medications are expensive, and unfortunately their immunogenicity contributes to loss of efficacy over time. Protein particles may form as a result of medication…Abstract Number: 1122 • ACR Convergence 2020
Osteoarthritis in a Large Integrated Health System Population: 18-Year Retrospective Review
Background/Purpose: Osteoarthritis (OA) is a mechanically and immunologically mediated common disease with a complex pathogenesis. Despite epidemiologic studies proving increasing age, obesity and female gender…Abstract Number: 1481 • ACR Convergence 2020
A Systematic Review to Quantify the Extent of Pharmaceutical Company Involvement in Rheumatology Consensus-Based Recommendations
Background/Purpose: Consensus-based recommendations guide standards of care for clinical practice. Pharmaceutical-industry involvement in producing such recommendations may undermine their objectivity. We performed a systematic review…Abstract Number: 1570 • ACR Convergence 2020
Immune Checkpoint Inhibitor Treatment in Cancer: Immunomodulator Use and Evaluation by Rheumatology
Background/Purpose: Immune checkpoint inhibitors (ICI) are used to treat an expanding number of cancers. Many cancer patients treated with ICI develop immune-related adverse events (irAE)…Abstract Number: 1637 • ACR Convergence 2020
Comparison of Nation-wide Epidemical Study on 2009 and That on 2019 Revealed That Improvement of Disease Severity and Mortality Rate May Come from Progress of Proficient Management in Patients with Relapsing Polychondritis in Japan
Background/Purpose: We conducted a retrospective survey study in 2009 and collected clinical data of 239 patients with relapsing polychondritis (RP). Using the survey data, we…Abstract Number: 1993 • ACR Convergence 2020
Cardiovascular Risk in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for cardiovascular (CV) events. While most RA patients use conventional disease-modifying antirheumatic drugs (DMARDs) such as…Abstract Number: 2000 • ACR Convergence 2020
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Background/Purpose: Prior studies suggest an increased risk of venous thromboembolism (VTE) among patients with rheumatoid arthritis (RA). However, little is known about the comparative risk…
ACR Meeting Abstracts